VNRX press release

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q(® )platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“In our Nu.Q(® )NETs pillar, in September we participated in the launch of DETECSEPS, a French government-funded €6.3 million program evaluating our automated Nu.Q(® )NETs assay as the sole biomarker for early detection of sepsis in hospital emergency departments.”

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“Furthermore, our rapid point-of-care finger-prick lateral flow prototype has demonstrated high correlation with our CE-marked automated assay in ICU sepsis patients.”

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“To accelerate commercialization and global market access, particularly in resource-constrained countries and humanitarian emergency settings, we signed in October a Letter of Intent with Missionpharma, a global distributor of healthcare products serving over 100 million patients annually.”

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“In Nu.Q(® )Cancer, we are advancing toward our French reimbursement submission for Nu.Q(® )Lung Cancer with support from our long-term collaborators at Hospices Civils de Lyon in France.”

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“For our novel Capture-Seq™ technology, following peer-reviewed publication of our clinical data in August, we are in active licensing discussions with several major liquid biopsy and diagnostic companies to target Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) opportunities representing combined annualized addressable markets estimated at over $36 billion¹.”

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“In our Nu.Q(® )Vet pillar, our clinical manuscript, submitted for peer review in May, demonstrated that our feline prototype assay detected 86% of feline lymphomas at 97% specificity.”

Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx

“I am personally leading our most advanced partner negotiations and, to underline my commitment to closing them, have voluntarily agreed to a further reduction in my base salary, effective November 1, 2026, such that my annual base salary is now 50% of its original level, until execution of a substantial licensing agreement. Furthermore, the chairman and entire board of directors have also agreed to reduce their cash fees by at least 50%”